{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T09:45:25Z","timestamp":1793785525316,"version":"4.6.1"},"reference-count":91,"publisher":"American Medical Association (AMA)","issue":"20","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2025,11,25]]},"abstract":"<jats:sec id=\"ab-jrv250030-1\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Lung cancer in nonsmoking individuals (defined as people who have smoked fewer than 100 cigarettes in their lifetime) accounts for 15% to 20% of all lung cancer cases worldwide. In the US, the annual incidence of lung cancer in nonsmoking individuals is 14.4 to 20.8 per 100\u202f000 person-years in females and 4.8 to 12.7 per 100\u202f000 person-years in males.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-jrv250030-2\">\n                    <jats:title>Observations<\/jats:title>\n                    <jats:p>\n                      Most lung cancers in nonsmoking individuals are histologically adenocarcinomas (60%-80%) with the remainder being squamous or adenosquamous (10%-20%) and rarely small cell lung cancer (&amp;amp;lt;10%). Risk factors include exposure to passive smoking, radon exposure, air pollution, asbestos, and history of lung cancer in a first-degree family member. Therapeutically targetable genomic variants, such as\n                      <jats:italic toggle=\"yes\">EGFR<\/jats:italic>\n                      mutations or\n                      <jats:italic toggle=\"yes\">ALK<\/jats:italic>\n                      gene rearrangements, are more common in tumors from nonsmoking individuals compared with those with a smoking history (defined as people who currently or formerly smoked) (43% vs 11% for\n                      <jats:italic toggle=\"yes\">EGFR<\/jats:italic>\n                      and 12% vs 2% for\n                      <jats:italic toggle=\"yes\">ALK<\/jats:italic>\n                      ). In contrast, tumor mutation burden, the number of somatic mutations in a tumor cell, is lower in lung cancer among nonsmoking individuals (0-3 mutations\/megabase [Mb] vs 0-30 mutations\/Mb). Similar to individuals with a history of smoking, nonsmoking individuals with lung cancer may present with wheeze, chest pain, dyspnea, hemoptysis, or symptoms attributable to metastatic disease (eg, bone pain and headache) or be diagnosed with incidentally detected disease. The US Preventive Services Task Force does not currently recommend lung cancer screening with low-dose computed tomographic scans for nonsmoking individuals, although screening guidelines vary globally. Treatment typically involves a combination of surgery, radiotherapy, and systemic therapies depending on stage, performance status, and molecular features of the tumor. Comprehensive next-generation sequencing should be performed on stage Ib to IIIa lung cancer tumor tissue from nonsmoking individuals because actionable genomic alterations, such as\n                      <jats:italic toggle=\"yes\">EGFR<\/jats:italic>\n                      mutations or\n                      <jats:italic toggle=\"yes\">ALK<\/jats:italic>\n                      gene rearrangements, are treated with targeted therapy such as the tyrosine kinase inhibitors osimertinib or lorlatinib, respectively. Median survival among nonsmoking individuals with advanced non\u2013small cell lung cancer (stage IIIb or higher) and actionable genomic alterations can exceed 3 to 5 years, while survival without these genomic alterations is similar to lung cancer in people with a history of smoking (1-2 years).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-jrv250030-3\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Lung cancer in nonsmoking individuals accounts for 15% to 20% of lung cancer cases worldwide. Among patients with lung cancer, nonsmoking individuals are more likely to have genomic alterations such as\n                      <jats:italic toggle=\"yes\">EGFR<\/jats:italic>\n                      mutations or\n                      <jats:italic toggle=\"yes\">ALK<\/jats:italic>\n                      gene rearrangements, and these patients have improved survival when treated with tyrosine kinase inhibitors compared with chemotherapy.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jama.2025.17695","type":"journal-article","created":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T15:31:06Z","timestamp":1760974266000},"page":"1836","source":"Crossref","is-referenced-by-count":51,"title":["Lung Cancer in Nonsmoking Individuals"],"prefix":"10.1001","volume":"334","author":[{"given":"Cian","family":"Murphy","sequence":"first","affiliation":[{"name":"Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, United Kingdom"},{"name":"The Royal Marsden Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tej","family":"Pandya","sequence":"additional","affiliation":[{"name":"Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, United Kingdom"},{"name":"UKRI UCL Centre for Doctoral Training in AI-enabled Healthcare Systems, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Swanton","sequence":"additional","affiliation":[{"name":"Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, United Kingdom"},{"name":"Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, United Kingdom"},{"name":"Department of Oncology, University College London Hospitals, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin J.","family":"Solomon","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia"},{"name":"Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"jrv250030r3","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024.","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"jrv250030r4","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djw295","article-title":"Proportion of never-smoker non-small cell lung cancer patients at three diverse institutions.","volume":"109","author":"Pelosof","year":"2017","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"jrv250030r5","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/s41571-023-00844-0","article-title":"Lung cancer in patients who have never smoked: an emerging disease.","volume":"21","author":"LoPiccolo","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"jrv250030r7","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"jrv250030r8","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/S2213-2600(24)00428-4","article-title":"Estimated worldwide variation and trends in incidence of lung cancer by histological subtype in 2022 and over time: a population-based study.","volume":"13","author":"Luo","year":"2025","journal-title":"Lancet Respir Med"},{"issue":"5","key":"jrv250030r11","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1200\/JCO.2006.07.2983","article-title":"Lung cancer incidence in never smokers.","volume":"25","author":"Wakelee","year":"2007","journal-title":"J Clin Oncol"},{"issue":"11","key":"jrv250030r12","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1038\/s41416-022-01736-3","article-title":"Association of smoking and polygenic risk with the incidence of lung cancer: a prospective cohort study.","volume":"126","author":"Zhang","year":"2022","journal-title":"Br J Cancer"},{"issue":"5","key":"jrv250030r13","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1002\/ijc.27339","article-title":"Cigarette smoking and lung cancer\u2013relative risk estimates for the major histological types from a pooled analysis of case-control studies.","volume":"131","author":"Pesch","year":"2012","journal-title":"Int J Cancer"},{"issue":"12","key":"jrv250030r14","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1002\/ijc.33765","article-title":"Incidence trends and risk factors of lung cancer in never smokers: pooled analyses of seven cohorts.","volume":"149","author":"Rissanen","year":"2021","journal-title":"Int J Cancer"},{"issue":"1","key":"jrv250030r15","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jtho.2021.07.031","article-title":"Screening for lung cancer in individuals who never smoked: an International Association for the Study of Lung Cancer Early Detection and Screening Committee Report.","volume":"17","author":"Kerpel-Fronius","year":"2022","journal-title":"J Thorac Oncol"},{"issue":"1","key":"jrv250030r16","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1093\/jnci\/djab143","article-title":"Incidence of lung cancer among never-smoking Asian American, Native Hawaiian, and Pacific Islander females.","volume":"114","author":"DeRouen","year":"2022","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"jrv250030r17","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/ijc.35188","article-title":"Lung cancer incidence rates in young women and men by state in the United States.","volume":"156","author":"Jemal","year":"2025","journal-title":"Int J Cancer"},{"issue":"11","key":"jrv250030r18","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1097\/CM9.0000000000002161","article-title":"Sex disparity of lung cancer risk in non-smokers: a multicenter population-based prospective study based on China National Lung Cancer Screening Program.","volume":"135","author":"Wu","year":"2022","journal-title":"Chin Med J (Engl)"},{"issue":"5","key":"jrv250030r19","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.jtho.2018.12.033","article-title":"The relationship between air pollution and lung cancer in nonsmokers in Taiwan.","volume":"14","author":"Tseng","year":"2019","journal-title":"J Thorac Oncol"},{"key":"jrv250030r20","doi-asserted-by":"publisher","DOI":"10.1016\/j.lansea.2024.100430","article-title":"Uniqueness of lung cancer in Southeast Asia.","volume":"27","author":"Noronha","year":"2024","journal-title":"Lancet Reg Health Southeast Asia"},{"issue":"5","key":"jrv250030r21","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1093\/jamia\/ocac020","article-title":"Inaccuracies in electronic health records smoking data and a potential approach to address resulting underestimation in determining lung cancer screening eligibility.","volume":"29","author":"Kukhareva","year":"2022","journal-title":"J Am Med Inform Assoc"},{"issue":"159","key":"jrv250030r25","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0230-2020","article-title":"Systematic review and meta-analysis of residential radon and lung cancer in never-smokers.","volume":"30","author":"Cheng","year":"2021","journal-title":"Eur Respir Rev"},{"issue":"26","key":"jrv250030r27","doi-asserted-by":"publisher","first-page":"43322","DOI":"10.18632\/oncotarget.17313","article-title":"Relationship between exposure to PM2.5 and lung cancer incidence and mortality: a meta-analysis.","volume":"8","author":"Huang","year":"2017","journal-title":"Oncotarget"},{"issue":"7955","key":"jrv250030r28","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/s41586-023-05874-3","article-title":"Lung adenocarcinoma promotion by air pollutants.","volume":"616","author":"Hill","year":"2023","journal-title":"Nature"},{"issue":"10","key":"jrv250030r30","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1093\/jjco\/hyw091","article-title":"Secondhand smoke exposure and risk of lung cancer in Japan: a systematic review and meta-analysis of epidemiologic studies.","volume":"46","author":"Hori","year":"2016","journal-title":"Jpn J Clin Oncol"},{"issue":"March","key":"jrv250030r31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18332\/tid\/202228","article-title":"Trends, differences, and future projections of lung cancer attributable to secondhand smoke across 204 countries and territories from 1990 to 2036.","volume":"23","author":"Yu","year":"2025","journal-title":"Tob Induc Dis"},{"key":"jrv250030r32","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.xjon.2023.10.031","article-title":"Risk of developing subsequent primary lung cancer after receiving radiation for breast cancer.","volume":"16","author":"Wong","year":"2023","journal-title":"JTCVS Open"},{"issue":"13","key":"jrv250030r33","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1016\/j.ejca.2012.01.038","article-title":"Increased risk of lung cancer in individuals with a family history of the disease: a pooled analysis from the International Lung Cancer Consortium.","volume":"48","author":"Cot\u00e9","year":"2012","journal-title":"Eur J Cancer"},{"issue":"8","key":"jrv250030r34","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1038\/s41588-022-01115-x","article-title":"Cross-ancestry genome-wide meta-analysis of 61,047 cases and 947,237 controls identifies new susceptibility loci contributing to lung cancer.","volume":"54","author":"Byun","year":"2022","journal-title":"Nat Genet"},{"issue":"12","key":"jrv250030r35","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1038\/ng1671","article-title":"Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR.","volume":"37","author":"Bell","year":"2005","journal-title":"Nat Genet"},{"issue":"20","key":"jrv250030r36","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1200\/JCO.2014.59.3590","article-title":"R331W missense mutation of oncogene YAP1 is a germline risk allele for lung adenocarcinoma with medical actionability.","volume":"33","author":"Chen","year":"2015","journal-title":"J Clin Oncol"},{"issue":"7","key":"jrv250030r37","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1200\/JCO.22.00857","article-title":"Clonal hematopoiesis and risk of incident lung cancer.","volume":"41","author":"Tian","year":"2023","journal-title":"J Clin Oncol"},{"issue":"33","key":"jrv250030r38","doi-asserted-by":"publisher","first-page":"3747","DOI":"10.1200\/JCO.21.01691","article-title":"Genomic profiling of lung adenocarcinoma in never-smokers.","volume":"39","author":"Devarakonda","year":"2021","journal-title":"J Clin Oncol"},{"issue":"6","key":"jrv250030r39","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1093\/oncolo\/oyac035","article-title":"Targeted next-generation sequencing reveals exceptionally high rates of molecular driver mutations in never-smokers with lung adenocarcinoma.","volume":"27","author":"Mack","year":"2022","journal-title":"Oncologist"},{"issue":"6312","key":"jrv250030r40","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1126\/science.aag0299","article-title":"Mutational signatures associated with tobacco smoking in human cancer.","volume":"354","author":"Alexandrov","year":"2016","journal-title":"Science"},{"issue":"6","key":"jrv250030r41","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/j.cell.2012.08.024","article-title":"Genomic landscape of non-small cell lung cancer in smokers and never-smokers.","volume":"150","author":"Govindan","year":"2012","journal-title":"Cell"},{"issue":"7463","key":"jrv250030r42","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer.","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"issue":"2","key":"jrv250030r43","first-page":"110","article-title":"Epidermal growth factor receptor in non-small cell lung cancer.","volume":"4","author":"Prabhakar","year":"2015","journal-title":"Transl Lung Cancer Res"},{"issue":"7","key":"jrv250030r44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2021.100194","article-title":"The genomics of young lung cancer: comprehensive tissue genomic analysis in patients under 40 with lung cancer.","volume":"2","author":"Gitlitz","year":"2021","journal-title":"JTO Clin Res Rep"},{"issue":"8","key":"jrv250030r45","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1002\/cncr.24181","article-title":"The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS.","volume":"115","author":"Wong","year":"2009","journal-title":"Cancer"},{"issue":"7","key":"jrv250030r46","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1080\/15384047.2015.1046649","article-title":"The RET fusion gene and its correlation with demographic and clinicopathological features of non-small cell lung cancer: a meta-analysis.","volume":"16","author":"Lin","year":"2015","journal-title":"Cancer Biol Ther"},{"issue":"9","key":"jrv250030r47","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/j.jtho.2018.05.026","article-title":"Characteristics and outcome of ROS1-positive non-small cell lung cancer patients in routine clinical practice.","volume":"13","author":"Park","year":"2018","journal-title":"J Thorac Oncol"},{"issue":"7216","key":"jrv250030r48","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1038\/nature07423","article-title":"Somatic mutations affect key pathways in lung adenocarcinoma.","volume":"455","author":"Ding","year":"2008","journal-title":"Nature"},{"issue":"10","key":"jrv250030r49","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1001\/jama.2021.1117","article-title":"Screening for lung cancer: US Preventive Services Task Force recommendation statement.","volume":"325","author":"Krist","year":"2021","journal-title":"JAMA"},{"issue":"5","key":"jrv250030r50","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S1470-2045(25)00082-8","article-title":"Low-dose CT for lung cancer screening in a high-risk population (SUMMIT): a prospective, longitudinal cohort study.","volume":"26","author":"Bhamani","year":"2025","journal-title":"Lancet Oncol"},{"issue":"5","key":"jrv250030r51","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1056\/NEJMoa1102873","article-title":"Reduced lung-cancer mortality with low-dose computed tomographic screening.","volume":"365","author":"Aberle","year":"2011","journal-title":"N Engl J Med"},{"issue":"6","key":"jrv250030r52","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa1911793","article-title":"Reduced lung-cancer mortality with volume CT screening in a randomized trial.","volume":"382","author":"de Koning","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"jrv250030r53","doi-asserted-by":"publisher","DOI":"10.1183\/20734735.0190-2023","article-title":"Lung cancer screening: where do we stand?","volume":"20","author":"Hardavella","year":"2024","journal-title":"Breathe (Sheff)"},{"issue":"1","key":"jrv250030r54","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s44276-023-00006-w","article-title":"Lung cancer in never smokers (LCINS): development of a UK national research strategy.","volume":"1","author":"Khan","year":"2023","journal-title":"BJC Rep"},{"issue":"2","key":"jrv250030r55","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S2213-2600(23)00338-7","article-title":"Low-dose CT screening among never-smokers with or without a family history of lung cancer in Taiwan: a prospective cohort study.","volume":"12","author":"Chang","year":"2024","journal-title":"Lancet Respir Med"},{"issue":"6","key":"jrv250030r56","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2020-001021","article-title":"Lung cancer symptoms at diagnosis: results of a nationwide registry study.","volume":"5","author":"Ruano-Ravi\u00f1a","year":"2020","journal-title":"ESMO Open"},{"key":"jrv250030r57","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.xjon.2022.11.021","article-title":"The majority of patients with resectable incidental lung cancers are ineligible for lung cancer screening.","volume":"13","author":"Zhou","year":"2022","journal-title":"JTCVS Open"},{"issue":"1","key":"jrv250030r58","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.lungcan.2015.01.020","article-title":"Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers.","volume":"88","author":"Rangachari","year":"2015","journal-title":"Lung Cancer"},{"issue":"5","key":"jrv250030r59","doi-asserted-by":"publisher","first-page":"450","DOI":"10.6004\/jnccn.2023.0026","article-title":"NCCN Guidelines insights: distress management, version 2.2023.","volume":"21","author":"Riba","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"jrv250030r60","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1001\/jama.2021.24287","article-title":"Evaluating the patient with a pulmonary nodule: a review.","volume":"327","author":"Mazzone","year":"2022","journal-title":"JAMA"},{"issue":"4","key":"jrv250030r61","doi-asserted-by":"publisher","first-page":"249","DOI":"10.6004\/jnccn.2204.0023","article-title":"Non-small cell lung cancer, version 4.2024, NCCN Clinical Practice Guidelines in Oncology.","volume":"22","author":"Riely","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"jrv250030r62","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/s41591-024-03216-y","article-title":"Ultrasensitive ctDNA detection for preoperative disease stratification in early-stage lung adenocarcinoma.","volume":"31","author":"Black","year":"2025","journal-title":"Nat Med"},{"issue":"11","key":"jrv250030r63","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1038\/s41591-022-02047-z","article-title":"Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer.","volume":"28","author":"Jee","year":"2022","journal-title":"Nat Med"},{"issue":"5","key":"jrv250030r64","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.11966","article-title":"Prediagnosis smoking cessation and overall survival among patients with non-small cell lung cancer.","volume":"6","author":"Wang","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"10","key":"jrv250030r65","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1200\/JCO.22.02186","article-title":"Adjuvant osimertinib for resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer: updated results from the phase III randomized ADAURA trial.","volume":"41","author":"Herbst","year":"2023","journal-title":"J Clin Oncol"},{"issue":"18","key":"jrv250030r66","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","article-title":"Osimertinib in resected EGFR-mutated non-small-cell lung cancer.","volume":"383","author":"Wu","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"jrv250030r67","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1056\/NEJMoa2304594","article-title":"Overall survival with osimertinib in resected EGFR-mutated NSCLC.","volume":"389","author":"Tsuboi","year":"2023","journal-title":"N Engl J Med"},{"issue":"14","key":"jrv250030r68","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1056\/NEJMoa2310532","article-title":"Alectinib in resected ALK-positive non-small-cell lung cancer.","volume":"390","author":"Wu","year":"2024","journal-title":"N Engl J Med"},{"issue":"7","key":"jrv250030r69","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1056\/NEJMoa2402614","article-title":"Osimertinib after chemoradiotherapy in stage III EGFR-mutated NSCLC.","volume":"391","author":"Lu","year":"2024","journal-title":"N Engl J Med"},{"issue":"2","key":"jrv250030r70","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jtho.2016.10.007","article-title":"Checkpoint inhibitors in metastatic EGFR-mutated non-small cell lung cancer: a meta-analysis.","volume":"12","author":"Lee","year":"2017","journal-title":"J Thorac Oncol"},{"issue":"19","key":"jrv250030r71","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1056\/NEJMoa2311926","article-title":"Perioperative nivolumab in resectable lung cancer.","volume":"390","author":"Cascone","year":"2024","journal-title":"N Engl J Med"},{"issue":"18","key":"jrv250030r72","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1056\/NEJMoa2304875","article-title":"Perioperative durvalumab for resectable non-small-cell lung cancer.","volume":"389","author":"Heymach","year":"2023","journal-title":"N Engl J Med"},{"issue":"10459","key":"jrv250030r73","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/S0140-6736(24)01756-2","article-title":"Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial.","volume":"404","author":"Spicer","year":"2024","journal-title":"Lancet"},{"issue":"2","key":"jrv250030r74","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer.","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"jrv250030r75","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC.","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N Engl J Med"},{"issue":"29","key":"jrv250030r76","doi-asserted-by":"publisher","first-page":"3400","DOI":"10.1200\/JCO.24.00581","article-title":"Lorlatinib versus crizotinib in patients with advanced ALK-positive non\u2013small cell lung cancer: 5-year outcomes from the phase III CROWN study.","volume":"42","author":"Solomon","year":"2024","journal-title":"J Clin Oncol"},{"issue":"16","key":"jrv250030r77","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1200\/JCO-25-00275","article-title":"Taletrectinib in ROS1+ non-small cell lung cancer: TRUST.","volume":"43","author":"P\u00e9rol","year":"2025","journal-title":"J Clin Oncol"},{"issue":"2","key":"jrv250030r78","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1056\/NEJMoa2302299","article-title":"Repotrectinib in ROS1 fusion-positive non-small-cell lung cancer.","volume":"390","author":"Drilon","year":"2024","journal-title":"N Engl J Med"},{"issue":"8","key":"jrv250030r79","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1093\/annonc\/mdz167","article-title":"Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.","volume":"30","author":"Mazieres","year":"2019","journal-title":"Ann Oncol"},{"key":"jrv250030r80","doi-asserted-by":"publisher","DOI":"10.1177\/17588359231161409","article-title":"Efficacy of immunotherapy in oncogene-driven non-small-cell lung cancer.","volume":"15","author":"Vokes","year":"2023","journal-title":"Ther Adv Med Oncol"},{"key":"jrv250030r81","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.100990","article-title":"The effect of smoking status on efficacy of immune checkpoint inhibitors in metastatic non-small cell lung cancer: a systematic review and meta-analysis.","volume":"38","author":"Dai","year":"2021","journal-title":"EClinicalMedicine"},{"issue":"5","key":"jrv250030r82","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1200\/JCO.21.02314","article-title":"Treatment for brain metastases: ASCO-SNO-ASTRO guideline.","volume":"40","author":"Vogelbaum","year":"2022","journal-title":"J Clin Oncol"},{"issue":"5","key":"jrv250030r83","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.prro.2023.04.004","article-title":"Treatment of oligometastatic non-small cell lung cancer: an ASTRO\/ESTRO clinical practice guideline.","volume":"13","author":"Iyengar","year":"2023","journal-title":"Pract Radiat Oncol"},{"issue":"10185","key":"jrv250030r84","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial.","volume":"393","author":"Palma","year":"2019","journal-title":"Lancet"},{"issue":"7","key":"jrv250030r88","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2400443","article-title":"Survival of patients with lung adenocarcinoma diagnosed in 2000, 2010, and 2020.","volume":"4","author":"Debieuvre","year":"2025","journal-title":"NEJM Evid"},{"issue":"8","key":"jrv250030r89","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/j.annonc.2020.04.478","article-title":"Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study.","volume":"31","author":"Mok","year":"2020","journal-title":"Ann Oncol"},{"issue":"8","key":"jrv250030r90","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1056\/NEJMoa1000678","article-title":"Early palliative care for patients with metastatic non-small-cell lung cancer.","volume":"363","author":"Temel","year":"2010","journal-title":"N Engl J Med"},{"issue":"9","key":"jrv250030r91","doi-asserted-by":"publisher","first-page":"S189","DOI":"10.1016\/j.jtho.2022.07.315","article-title":"EP01.06-003 Female Asian Nonsmoker Screening Study (FANSS): exploring lung cancer screening in a high risk population.","volume":"17","author":"Shum","year":"2022","journal-title":"J Thorac Oncol"},{"key":"jrv250030r1","unstructured":"International Agency for Research on Cancer, World Health Organization. Lung Cancer Awareness Month 2024. November 4, 2024. Accessed January 17, 2025. https:\/\/www.iarc.who.int\/featured-news\/lung-cancer-awareness-month-2024"},{"key":"jrv250030r2","unstructured":"American Lung Association. Overall tobacco trends. Updated May 30, 2024. Accessed September 12, 2025. https:\/\/www.lung.org\/research\/trends-in-lung-disease\/tobacco-trends-brief\/overall-smoking-trends"},{"key":"jrv250030r6","unstructured":"World Health Organization. Lung cancer. June 26, 2023. Accessed January 16, 2025. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/lung-cancer"},{"key":"jrv250030r9","unstructured":"All You Need Is Lungs. Accessed January 17, 2025. https:\/\/www.allyouneedislungs.org.uk"},{"key":"jrv250030r10","unstructured":"See through the symptoms. Accessed January 17, 2025. https:\/\/www.seethroughthesymptoms.uk"},{"key":"jrv250030r22","unstructured":"National Cancer Institute. SEER*Explorer: all cancer sites combined: recent trends in SEER age-adjusted incidence rates, 2000-2022. Accessed October 11, 2024. https:\/\/seer.cancer.gov\/statistics-network\/explorer\/"},{"key":"jrv250030r23","unstructured":"US Environmental Protection Agency. What is EPA\u2019s action level for radon and what does it mean? February 19, 2019. Accessed May 8, 2025. https:\/\/www.epa.gov\/radon\/what-epas-action-level-radon-and-what-does-it-mean"},{"key":"jrv250030r24","unstructured":"US Environmental Protection Agency. Health risk of radon. February 27, 2024. Accessed October 29, 2024. https:\/\/www.epa.gov\/radon\/health-risk-radon"},{"key":"jrv250030r26","unstructured":"Environmental Protection Agency. Consumer\u2019s guide to radon reduction: how to fix your home. Accessed September 12, 2025. https:\/\/www.epa.gov\/sites\/default\/files\/2016-12\/documents\/2016_consumers_guide_to_radon_reduction.pdf"},{"key":"jrv250030r29","unstructured":"International Agency for Research on Cancer, World Health Organization. Agents classified by the IARC Monographs, volumes 1-137. Accessed March 27, 2025. https:\/\/monographs.iarc.who.int\/agents-classified-by-the-iarc"},{"key":"jrv250030r85","unstructured":"NHS England. Cancer survival in England, cancers diagnosed 2016 to 2020, followed up to 2021. Accessed June 8, 2025. https:\/\/digital.nhs.uk\/data-and-information\/publications\/statistical\/cancer-survival-in-england\/cancers-diagnosed-2016-to-2020-followed-up-to-2021"},{"key":"jrv250030r86","unstructured":"American Society of Clinical Oncology. ASCO guidelines: thoracic cancer. Accessed July 2, 2025. https:\/\/ascopubs.org\/topics\/asco-guidelines\/thoracic-cancer"},{"key":"jrv250030r87","unstructured":"European Society for Medical Oncology. ESMO clinical practice guidelines: lung and chest tumours. Accessed July 2, 2025. https:\/\/www.esmo.org\/guidelines\/esmo-clinical-practice-guidelines-lung-and-chest-tumours"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2840343\/jama_murphy_2025_rv_250030_1763752227.36128.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T16:00:55Z","timestamp":1764086455000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2840343"}},"subtitle":["A Review"],"short-title":[],"issued":{"date-parts":[[2025,11,25]]},"references-count":91,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2025,11,25]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2025.17695","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,25]]}}}